Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2013; 19(2): 299-303
Published online Jan 14, 2013. doi: 10.3748/wjg.v19.i2.299
Published online Jan 14, 2013. doi: 10.3748/wjg.v19.i2.299
Yes | No | Our patient | |
Are there previous conclusive reports on this reaction? | 1 | 0 | 0 |
Did the adverse event appear after the suspected drug was administered? | 2 | -1 | 2 |
Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? | 1 | 0 | 1 |
Did the adverse reaction reappear when the drug was readministered? | 2 | -1 | 2 |
Are there alternative causes (other than the drug) that could have, on their own, caused the reaction? | -1 | 2 | 2 |
Did the reaction appear when a placebo was given? | -1 | 1 | 1 |
Was the drug detected in the blood (or other fluids) in concentration known to be toxic? | 1 | 0 | 0 |
Was the reaction more severe when the dose was increased or less severe when dose was decreased? | 1 | 0 | 0 |
Did the patient have a similar reaction to the same or similar drugs in any previous exposure? | 1 | 0 | 1 |
Was the adverse event confirmed by any objective evidence? | 1 | 0 | 1 |
10 |
- Citation: Sherid M, Sifuentes H, Samo S, Deepak P, Sridhar S. Lubiprostone induced ischemic colitis. World J Gastroenterol 2013; 19(2): 299-303
- URL: https://www.wjgnet.com/1007-9327/full/v19/i2/299.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i2.299